- Home
- CERT vs KURA Comparison
CERT vs KURA Comparison
Compare CERT & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CERT | KURA |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 860.9M | 765.8M |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CERT | KURA |
|---|---|---|
| Price | $6.33 | $9.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 11 |
| Target Price | $11.67 | ★ $25.56 |
| AVG Volume (30 Days) | ★ 2.5M | 1.1M |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.50 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $418,838,000.00 | $67,482,000.00 |
| Revenue This Year | $4.18 | $28.28 |
| Revenue Next Year | $5.39 | $106.37 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 8.75 | ★ 25.24 |
| 52 Week Low | $5.19 | $5.45 |
| 52 Week High | $13.88 | $12.49 |
Technical Indicators
Market Signals| Indicator | CERT | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 55.41 | 57.61 |
| Support Level | $5.93 | $9.08 |
| Resistance Level | $6.48 | $9.60 |
| Average True Range (ATR) | 0.28 | 0.38 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 76.87 | 59.80 |
Price Performance
Historical ComparisonAbout CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.